Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Total Liabilities
Everything the company owes to creditors and other parties.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 60.1% from a year ago
Total liabilities stood at $26.7M at the end of Q1 FY2026, up 60.1% from a year earlier and up 41.0% from the prior quarter. Over 3 fiscal years it compounded at +79.3% a year.
Context
- Total liabilities amounted to 41.5% of total assets at the end of Q1 FY2026, down 18.2 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +60.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 18.94M USD
- Year-over-year change
- -21.9%
- 4-year CAGR
- +70.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.94M | -21.9% |
| FY2024 | 2024-12-31 | 24.24M | +34.6% |
| FY2023 | 2023-12-31 | 18M | +448.1% |
| FY2022 | 2022-12-31 | 3.28M | +45.3% |
| FY2021 | 2021-12-31 | 2.26M | — |
Total Liabilities vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +60.1% is the 3rd highest of 10, against a peer median of +5.1%.
- Total liabilities amounts to 41.5% of total assets for UNCY, versus a peer median of 35.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $288.72M USD | +10.6% | +165.2% | 89.1% |
| Mar 2026 | $85.94M USD | -23.9% | +31.5% | 47.7% | |
| Mar 2026 | $74.56M USD | +565.6% | — | 70.7% | |
| Mar 2026 | $38.51M USD | +49.2% | +29.7% | 20.3% | |
| Mar 2026 | $27.67M USD | +5.1% | +11.8% | 59.6% | |
| Mar 2026 | $26.7M USD | +60.1% | +79.3% | 41.5% | |
| Mar 2026 | $16.63M USD | +217.4% | -15.6% | 7.1% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $12.32M USD | -22.8% | +17.0% | 11.4% |
| Mar 2026 | $8.6M USD | -18.2% | -21.3% | 8.9% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$8.19M CAD | -59.9% | +4.3% | 35.4% |
| Peer median (excluding UNCY) | — | +5.1% | +14.4% | 35.4% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.